Publications

summer 1992
Article

Governance, Contracting, and Investment Time Horizons: A Look at Japan and Germany

By: W. C. Kester

Keywords: Governance; Investment; Japan; Germany

Other Article

Want to See the Future of Digital Health Tools? Look to Germany

By: Ariel Dora Stern, Henrik Matthies, Julia Hagen, Jan B. Brönneke and Jörg F. Debatin

A new law will make it easier to introduce and determine the benefits of new tools. Perhaps its most important provisions are its formalization of “prescribable applications,” which include standard software, SaaS, and mobile as well as browser-based apps, and the... View Details

Keywords: Health Care and Treatment; Transformation; Internet and the Web; Technological Innovation; Germany

Register to Read

December 2000
Article

Risk versus Risk: Tragic Choices in Drug Regulation in the United States and Germany

By: Arthur A. Daemmrich

Keywords: Risk and Uncertainty; Decision Choices and Conditions; Health; United States; Germany

October 2012
Case

Germany's Green Energy Revolution

By: Noel Maurer, Elena Corsi, Emilie Billaud and Emer Moloney

Keywords: Europe; Germany; Energy; Energy Industry; Europe; Germany

1994
Article

Cross-Investments in Transnational Banking: Britain, Germany and the United States in the Twentieth Century

By: G. Jones

Keywords: Investment; Banks and Banking; Business History; Banking Industry; United Kingdom; Germany; United States

2006
Chapter

BioRisk: interleukin-2 from laboratory to market in the United States and Germany

By: Arthur A. Daemmrich

Keywords: Product Development; Risk and Uncertainty; Health Testing and Trials; Pharmaceutical Industry; Biotechnology Industry; United States; Germany

July 2019
Article

The Impact of Price Regulation on the Availability of New Drugs in Germany

By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari

The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details

Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany

Read Now

August 2012
Case

Messer Griesheim (A) (Abridged)

By: Josh Lerner, Eva Lutz and Kerry Herman

In 2001, Allianz Capital Partners and Goldman Sachs acquired a majority stake in Messer Griesheim, a European industrial gas concern held by Hoechst. The dealmakers faced several challenges, including delicate corporate governance issues due to partial family... View Details

Keywords: Germany; Energy; Private Equity; Venture Capital; Energy Industry; European Union

April 2002
Article

A Tale of Two Experts: Thalidomide and Political Engagement in the United States and West Germany

By: Arthur A. Daemmrich

Keywords: Health; Government and Politics; Pharmaceutical Industry; United States; Germany

2002
Working Paper

The Rise of Consumer Politics: Market Institutions and Product Choice in Postwar France and Germany

By: Gunnar Trumbull

April 1984
Teaching Note

Founding of the European Economic Community & Germany (A): The Rebirth of an Economy, Teaching Note

By: Bruce R. Scott

Keywords: Trade; Germany; European Union

October 20, 2021
Other Article

On the Brink of a Digital Health Care Transformation: What Germany Can Learn from the United States

By: Yoni Goldwasser, William J. Gordon, Jan B. Brönneke and Ariel D. Stern

Read Now

18 Jun 2024
News

Empire of Ideas: Creating the Modern University from Germany to America to China with William C. Kirby

April 2016 (Revised January 2018)
Supplement

Project Deutschland: Unpeeling the Onion of a Distressed Real Estate Portfolio

By: Nori Gerardo Lietz and Ricardo Andrade

Keywords: Real Estate; Germany; Distress Investing; Non-performing Loan; Borrowing and Debt; Capital Structure; Private Equity; Negotiation Deal; Valuation; Real Estate Industry; Financial Services Industry; Germany; Europe

January 2016
Case

SAP SE: Autism at Work

By: Gary P. Pisano and Robert D. Austin

This case describes SAP's "Autism at Work" program, which integrates people with autism into the company's workforce. The company has a stated objective of making 1% of its workforce people with autism by 2020. SAP's rationale for the program is based on the belief... View Details

Keywords: Software; Human Resource Management; Diversity Management; Germany; Selection and Staffing; Innovation and Management; Applications and Software; Recruitment; Diversity; Information Technology Industry; Germany

March 2013 (Revised March 2013)
Case

Rough Justice: Stuart Eizenstat and Holocaust-era Asset Restitution (A)

By: James K. Sebenius and Laurence A. Green

Beginning in 1994, a series of articles and public disclosures indicated that Swiss banks may have retained assets belonging to victims of the Holocaust, and also may have engaged in long term attempts to block survivors' ability to recover those assets after World War... View Details

Keywords: Banking; Banking And Insurance; U.s. History; Germany; Europe; Governance; History; Negotiation; Business and Government Relations; Banking Industry; Insurance Industry; Germany; United States; Switzerland

June 2015
Supplement

Henkel: Building a Winning Culture (B)

By: Robert Simons and Natalie Kindred

This case, an update on "Henkel: Building a Winning Culture (A)," describes Henkel's strong performance against its tough 2012 objectives, as well as the new objectives CEO Kasper Rorsted set for 2016. View Details

Keywords: Kasper Rorsted; Rorsted; Henkel; Germany; Personal Care; Consumer Products; Culture; Performance Management; Performance Metrics; Stretch Goals; Strategy; Measurement and Metrics; Performance; Management; Consumer Products Industry; Germany

March 24, 2014
Article

Like a Boss: How Corporate Negotiators Would Handle Nuclear Talks With Iran

By: James K. Sebenius

While the Obama team deserves high marks for launching the interim talks, its approach doesn't sell the upside of a comprehensive deal persuasively enough to transform more Iranian skeptics into active supporters—a necessary condition for success if there is an... View Details

Read Now

November 2016 (Revised March 2018)
Case

Deutsche Bank: Structured Retail Products

By: Boris Vallée and Jérôme Lenhardt

Describes how Deutsche Bank, a leading European bank, is deciding whether or not to launch a new structured retail product in Germany: an autocallable note. Will this product find a market and how does it fit into the bank’s product portfolio? The case investigates how... View Details